
Opinion|Videos|June 19, 2024
Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
- Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
Value-Based Care Offers Solutions to Patient Access Challenges: Brian Mulherin, MD
3
New WHO Reports Sounds Alarm on Antimicrobial Resistance
4
Why Education and Collaboration Are Key to Bispecific Therapy Administration: Amir Fathi, MD
5